Trial: 201710050

A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed
by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission

Phase

III

Principal Investigator

Cashen, Amanda

Disease Site

Non-Hodgkin’s Lymphoma

Learn more about this study at: clinicaltrials.gov